News

Healthcare — latest

  1. HealthcareJNJ▲ +0.79%· via Yahoo

    Johnson & Johnson Executives Outline Growth Plan Through STELARA Biosimilar Transition

    Johnson & Johnson (JNJ) common stock gained 0.79% to close at $267.69. Company executives told a Morgan Stanley event the firm expects to grow through biosimilar competition for STELARA, with its medicines, medical devices and pipeline supporting accelerating growth through decade-end. The stock is positioned at 87.6% of the band in its 52-week range and has returned 51.08% over one year.

  2. HealthcareMRK▲ +0.64%· via SeekingAlpha

    Merck & Co shares rise 0.64% as CEO speaks at Morgan Stanley healthcare conference

    Merck & Co Inc (MRK) common stock gained 0.64% to $144.85 during Monday's session. Chief executive Robert Davis presented at Morgan Stanley's healthcare conference on September 14, 2026. The stock has returned 71.28% over the past year and trades at 84.8% of its 52-week range.

  3. HealthcareLLY▲ +2.02%· via SeekingAlpha

    Eli Lilly shares rise 2.0% as executive speaks at Morgan Stanley healthcare conference

    Eli Lilly and Co (LLY) common stock gained 2.02% to $1138.28. Executive Ilya Yuffa presented at the Morgan Stanley healthcare conference on September 14, 2026. The stock has returned 47.85% over the past year and trades at 73.4% of its 52-week range.

  4. HealthcarePFE▲ +0.00%· via Yahoo

    Pfizer CEO Says Company Has Addressed Policy and COVID Headwinds

    Pfizer Inc (PFE) common stock closed flat at $27.72. Chief Executive Officer Albert Bourla told a Morgan Stanley conference that the drugmaker has addressed policy uncertainty, declining COVID-19 demand, and upcoming patent losses, while focusing on its pipeline and obesity plans. The stock has gained 12.82% over one year and trades at 73.5% of its 52-week range.

  5. HealthcareUNH▲ +1.18%· via Yahoo

    UnitedHealth shares gain 1.18% as UBS comments on Medicare Advantage outlook

    UnitedHealth Group Inc (UNH) common stock rose 1.18% to $383.55, trading above its 20-day average volume at 1.64x. UBS stated that the company's earnings growth outlook is unlikely to change ahead of Medicare Advantage rate announcements. The stock has gained 36.83% over six months.

  6. HealthcareABT▲ +1.21%· via Yahoo

    Abbott Laboratories Settles DOJ Probe Over 2022 Formula Recall

    Abbott Laboratories (ABT) common stock rose 1.21% to $103.18. The company reached a settlement with the Department of Justice to resolve an investigation and lawsuits from federal and state authorities relating to manufacturing practices and the 2022 powdered infant formula recall at its Sturgis, Michigan facility. The stock trades 38.2% into its 52-week range of $81.97 to $137.49.

  7. HealthcareISRG▲ +2.00%· via Yahoo

    Intuitive Surgical shares rise 2.00% after trading 38% below 52-week high

    Intuitive Surgical Inc (ISRG) common stock rose 2.00% to close at $376.52, trading 17.4% into its 52-week range of $328.57 to $603.88. The medical robotics company has seen its shares decline 22.98% over six months amid slower growth in US robotic-surgery procedures. Volume reached 1.52 times the 20-day average during the session.

  8. HealthcarePFE▲ +0.35%· via Yahoo

    Pfizer Inc (PFE) trades at $27.82 as dividend sustainability questioned

    Pfizer Inc (PFE) closed at $27.82, up 0.35% on the session. Yahoo Finance raised concerns about the sustainability of the company's 6% dividend yield amid patent expirations and balance sheet constraints. The stock sits 75.3% of the way through its 52-week range of $23.58 to $29.21.

  9. HealthcareAMGN▼ -0.10%· via Yahoo

    Amgen Inc (AMGN) slips 0.10% to $376.98 amid increased user attention

    Amgen Inc (AMGN) fell 0.10% to close at $376.98 in below-average volume of 0.87 times its 20-day mean. Zacks.com reported heightened user interest in the biotechnology stock. The shares have gained 35.49% over the past year but trade 5.45% below their 50-day average.

  10. HealthcareUNH▼ -2.37%· via Yahoo

    UnitedHealth Group declares $2.32 quarterly dividend, ex-date Sept. 14

    UnitedHealth Group Inc (UNH) common stock fell 2.37% to $379.09. The company announced a $2.32 per share cash dividend payable on 2026-09-22, with shareholders of record required before the ex-dividend date of 2026-09-14. The stock has returned 36.83% over six months.

  11. HealthcareMRNA▼ -0.76%· via SeekingAlpha

    Moderna Inc (MRNA) Shares Slip 0.76% Following Phase 3 Melanoma Trial Results

    Moderna Inc (MRNA) common stock closed at $142.88, down 0.76% from the previous session. The decline followed analyst commentary from SeekingAlpha assigning a Sell rating on valuation grounds after the company reported Phase 3 melanoma trial data. The stock has gained 492.23% over the past year, positioning it at 78.1% of its 52-week range.

  12. HealthcareMRK▼ -0.54%· via Yahoo

    Merck & Co strikes clinical trial deal with Perspective Therapeutics for cancer combination study

    Merck & Co Inc (MRK) common stock fell 0.54% to $143.93. The pharmaceutical company entered a clinical trial collaboration and supply agreement with Perspective Therapeutics to test targeted alpha-particle therapy [212Pb]PSV359 combined with Keytruda (pembrolizumab) in FAP-α positive solid tumors. Merck has gained 71.28% over the past year.

  13. HealthcareLLY▼ -0.65%· via Yahoo

    Eli Lilly edges lower as Novartis pelacarsen trial failure reshapes drug race

    Eli Lilly and Co (LLY) common stock declined 0.65% to $1115.70 on below-average volume of 0.74x its 20-day mean. Novartis disclosed that its pelacarsen candidate failed in clinical trials, a development that may have limited impact on Lilly's competing programs. The stock has gained 47.85% over one year.

  14. HealthcareAMGN▼ -1.34%· via Yahoo

    Amgen shares fall 1.34% as CFO discusses product portfolio at Wells Fargo event

    Amgen Inc (AMGN) common stock closed at $377.35, down 1.34% from the previous session. Chief Financial Officer Thomas Dittrich spoke at a Wells Fargo biotech and pharma discussion, addressing the company's commercial products, late-stage development programs, and capital allocation strategy. The stock trades 4.09% below its 50-day average, with a market cap of $236.9B.

  15. HealthcareMRK▲ +0.14%· via Yahoo

    Merck Shares Edge Up 0.14% as Company Prepares for Keytruda Patent Expiry

    Merck & Co Inc (MRK) common stock rose 0.14% to $144.91 in below-average volume. The company is building out its pipeline and newer drug portfolio to mitigate the impact of Keytruda's loss of exclusivity in 2028. The stock has returned 71.03% over the past year.

  16. HealthcareBMY▼ -0.64%· via Yahoo

    Bristol-Myers Squibb Shares Slip 0.64% Despite Positive CAR-T Trial Data

    Bristol-Myers Squibb Co (BMY) common stock fell 0.64% to $63.34 despite positive clinical news. The company announced that its experimental CAR-T cell therapy arlocabtagene autoleucel met the primary endpoint in a mid-stage trial for advanced multiple myeloma patients who had received four prior treatment classes, showing statistically significant improvement in overall response rates. The stock has gained 34.98% over the past year.

  17. HealthcareABBV▲ +0.90%· via Yahoo

    AbbVie Shares Rise 0.90% as Migraine Drug Succeeds in Phase 3 Trial

    AbbVie Inc (ABBV) closed at $257.31, up 0.90% on the session. The biotechnology company announced positive results from its LUNA study, in which atogepant met primary endpoints for menstrual-related migraine prevention. The stock has gained 21.19% over the past year.

  18. HealthcareAMGN▼ -0.81%· via Yahoo

    Amgen Inc (AMGN) falls 0.81% as volume runs above average

    Amgen Inc (AMGN) closed at $379.37, down 0.81% on the session, with volume running at 1.33x its 20-day average. The biotechnology company has gained 36.61% over the past year despite trading 4.09% below its 50-day moving average. Its RSI of 24.4 suggests oversold conditions following recent declines from the 52-week high of $447.03.

  19. HealthcareUNH▼ -2.59%· via CNBC

    Capital Wealth Planning adds UnitedHealth position at $378

    UnitedHealth Group Inc (UNH) closed at $378.24, down 2.59% in the session. Kevin Simpson, founder and chief investment officer of Capital Wealth Planning, disclosed he is purchasing shares of the health insurer. The stock trades 10.08% above its 200-day moving average and has returned 36.12% over six months.

  20. HealthcareLLY▼ -0.68%· via Yahoo

    Eli Lilly closes purchase of clinical-stage mental health developer AtaiBeckley

    Eli Lilly and Co (LLY) traded down 0.68% to $1115.39 on the session. The pharmaceutical company announced it has closed its purchase of AtaiBeckley Inc., a clinical-stage biopharmaceutical firm working on rapid-acting neuroplastogens including BPL-003 for treatment-resistant depression. Lilly's stock sits 69.5% of the way through its 52-week range of $712.05 to $1292.65.

  21. HealthcareABT▼ -0.73%· via Yahoo

    Abbott Laboratories (ABT) declines 0.73% amid elevated search interest

    Abbott Laboratories (ABT) fell 0.73% to $102.61, extending its one-year decline to 21.67%. The health care company has drawn increased attention from retail investors despite trading at 37.2% of its 52-week range. Its RSI reading of 23.9 indicates technically oversold territory.

  22. HealthcareABBV▲ +1.63%· via Yahoo

    AbbVie shares gain 1.63% after Phase III trial success in menstrual migraine

    AbbVie Inc (ABBV) common stock rose 1.63% to $255.00 following positive Phase III results for Qulipta in menstrual migraine prevention. The company is pursuing approval for the new indication in a market where no targeted therapies are currently approved. The stock trades at 83.7% of its 52-week range.

  23. HealthcareLLY▼ -0.11%· via ChartMill

    Eli Lilly Trades at $1123 With RSI at 9.7 Amid Technical Analysis Coverage

    Eli Lilly and Co (LLY) common stock closed at $1123.00, down 0.11% in the session. ChartMill highlighted the pharmaceuticals company for what it characterized as strong growth and high profitability alongside a consolidating chart pattern. The stock sits at 70.8% of its 52-week range despite an RSI reading of 9.7.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy